Non-alcoholic fatty liver disease: Definition and subtypes
Seul Ki Han, Soon Koo Baik, Moon Young Kim
Clin Mol Hepatol. 2023;29(suppl):S5-S16.   Published online 2022 Dec 28     DOI: https://doi.org/10.3350/cmh.2022.0424
Citations to this article as recorded by Crossref logo
The interplay between chronic hepatitis B and diabetes mellitus: A narrative and concise review
Shang‐Chin Huang, Jia‐Horng Kao
The Kaohsiung Journal of Medical Sciences.2024; 40(1): 6.     CrossRef
LncRNA Gm28382 promotes lipogenesis by interacting with miR-326-3p to regulate ChREBP signaling pathway in NAFLD
Sen Yang, Yang Zhang, Yan Zhang, Lianhong Yin, Xu Han, Xuerong Zhao, Ning Wang, Lina Xu
International Immunopharmacology.2024; 127: 111444.     CrossRef
Role of Perturbated Hemostasis in MASLD and Its Correlation with Adipokines
Salvatore Pezzino, Tonia Luca, Mariacarla Castorina, Stefano Puleo, Saverio Latteri, Sergio Castorina
Life.2024; 14(1): 93.     CrossRef
From Nonalcoholic Fatty Liver Disease to Metabolic Dysfunction-Associated Steatotic Liver Disease: Out with the Old, in with the New
Iyiad Alabdul Razzak, Mazen Noureddin, Hirsh Trivedi
Journal of Clinical Medicine.2024; 13(3): 880.     CrossRef
Research Progress of MIF in Nonalcoholic Fatty Liver Disease
·阿不力提浦 阿依古扎丽
Advances in Clinical Medicine.2024; 14(02): 2483.     CrossRef
Hepatic Stellate Cell‐Targeting Micelle Nanomedicine for Early Diagnosis and Treatment of Liver Fibrosis
Lei Wang, Jieying Zhou, Jian Wang, Xiaotang Wang, Haijuan Dong, Lingzhi Zhao, Junchen Wu, Juanjuan Peng
Advanced Healthcare Materials.2024;[Epub]     CrossRef
Not Only Metabolic Complications of Childhood Obesity
Sebastian Ciężki, Emilia Odyjewska, Artur Bossowski, Barbara Głowińska-Olszewska
Nutrients.2024; 16(4): 539.     CrossRef
Effect of Statins for Primary Prevention of Cardiovascular Disease According to the Fatty Liver Index
Joonsang Yoo, Jimin Jeon, Minyoul Baik, Jinkwon Kim
Journal of Epidemiology and Global Health.2024;[Epub]     CrossRef
Ferroptosis in Liver Disease: Natural Active Compounds and Therapeutic Implications
Zhili Wu, Yanru Zhu, Wenchao Liu, Balamuralikrishnan Balasubramanian, Xiao Xu, Junhu Yao, Xinjian Lei
Antioxidants.2024; 13(3): 352.     CrossRef
Lipidomic Analysis of Liver and Adipose Tissue in a High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease Mice Model Reveals Alterations in Lipid Metabolism by Weight Loss and Aerobic Exercise
Thomai Mouskeftara, Olga Deda, Grigorios Papadopoulos, Antonios Chatzigeorgiou, Helen Gika
Molecules.2024; 29(7): 1494.     CrossRef
Puerarin Induces Macrophage M2 Polarization to Exert Antinonalcoholic Steatohepatitis Pharmacological Activity via the Activation of Autophagy
Xiaoxue Fang, Xintian Lan, Ming Zhu, Min He, Mengmeng Sun, Yiming Cao, Difu Zhu, Dean Guo, Haoming Luo
Journal of Agricultural and Food Chemistry.2024; 72(13): 7187.     CrossRef
Lean vs. obese phenotypes of nonalcoholic fatty liver disease: similar or different?
Ho Soo Chun, Minjong Lee
Clinical and Molecular Hepatology.2023; 29(2): 377.     CrossRef
The Janus-Faced Role of Lipid Droplets in Aging: Insights from the Cellular Perspective
Nikolaus Bresgen, Melanie Kovacs, Angelika Lahnsteiner, Thomas Klaus Felder, Mark Rinnerthaler
Biomolecules.2023; 13(6): 912.     CrossRef
Protective effects of statins on the incidence of NAFLD–related decompensated cirrhosis in T2DM
Szu‐Yuan Wu, Wan‐Ming Chen, Ming‐Feng Chiang, Hung‐Chieh Lo, Ming‐Shun Wu, Ming‐Che Lee, Ruey‐Shyang Soong
Liver International.2023; 43(10): 2232.     CrossRef
Editorial: Will MRI‐PDFF become the new standard for steatosis assessment in NAFLD?
Angeliki Pappa, Tobias Wenzl
Alimentary Pharmacology & Therapeutics.2023; 58(3): 364.     CrossRef
Letter regarding “Non-alcoholic fatty liver disease: Definition and subtypes”
Seogsong Jeong, Yohwan Lim, Su Kyoung Lee, Hyun Wook Han
Clinical and Molecular Hepatology.2023; 29(3): 810.     CrossRef
Non-Alcoholic Fatty Liver Disease and Echocardiographic Parameters of Left Ventricular Diastolic Function: A Systematic Review and Meta-Analysis
Athina Goliopoulou, Panagiotis Theofilis, Evangelos Oikonomou, Artemis Anastasiou, Panteleimon Pantelidis, Maria Ioanna Gounaridi, Georgios E. Zakynthinos, Ourania Katsarou, Eva Kassi, Vaia Lambadiari, Dimitris Tousoulis, Manolis Vavuranakis, Gerasimos Si
International Journal of Molecular Sciences.2023; 24(18): 14292.     CrossRef
Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity
Gi-Ae Kim, Joon Ho Moon, Won Kim
Clinical and Molecular Hepatology.2023; 29(4): 831.     CrossRef
Association between Impaired Ketogenesis and Metabolic-Associated Fatty Liver Disease
Jaehyun Bae, Byung-Wan Lee
Biomolecules.2023; 13(10): 1506.     CrossRef
The evolving role of lenvatinib at the new era of first-line hepatocellular carcinoma treatment
Landon L. Chan, Stephen L. Chan
Clinical and Molecular Hepatology.2023; 29(4): 909.     CrossRef
Comparison of the efficacy and safety of hypoglycemic treatments in patients with non-alcoholic fatty liver disease and type-2 diabetes: a systematic review and Bayesian network analysis
Nuojin Guo, Hekai Shi, Hao Zhang, Hua Wang
European Journal of Clinical Pharmacology.2023; 79(11): 1465.     CrossRef
Clinical Classification of Obesity and Implications for Metabolic Dysfunction-Associated Fatty Liver Disease and Treatment
Yuping Ding, Quanjun Deng, Mei Yang, Haiyan Niu, Zuoyu Wang, Shihai Xia
Diabetes, Metabolic Syndrome and Obesity.2023; Volume 16: 3303.     CrossRef